What are the effects and risks of ACE inhibitor therapy in Black patients with uncomplicated primary hypertension?

ACE Inhibitors in Black Patients with Uncomplicated Hypertension

In Black patients with uncomplicated primary hypertension (without heart failure, chronic kidney disease, or diabetes with nephropathy), ACE inhibitors should NOT be used as initial monotherapy; instead, start with a thiazide-type diuretic or calcium channel blocker (CCB). 1

Initial Therapy Recommendations

The 2017 ACC/AHA Hypertension Guidelines provide Class I, Level B evidence that thiazide-type diuretics or CCBs are the preferred first-line agents for Black patients with hypertension who do not have compelling indications for other agents 1.

Why Not ACE Inhibitors as Monotherapy?

Blood Pressure Efficacy:

• ACE inhibitors produce a blunted blood pressure response in Black patients compared to thiazide diuretics and CCBs when used as monotherapy 1
• Meta-analysis demonstrates Black patients experience 4.6 mmHg less systolic BP reduction and 2.8 mmHg less diastolic BP reduction with ACE inhibitors compared to white patients 2
• In the landmark ALLHAT trial, lisinopril was less effective than chlorthalidone in lowering BP in Black patients 3

Clinical Outcomes:

• Thiazide diuretics are superior to ACE inhibitors for preventing cardiovascular events in Black patients 1
• In ALLHAT, Black patients on lisinopril had significantly higher rates of:
  • Stroke: 40% increased risk (RR 1.40,95% CI 1.17-1.68) compared to chlorthalidone 3
  • Combined CVD events: 19% increased risk (RR 1.19,95% CI 1.09-1.30) 3
  • Heart failure: 30% increased risk (RR 1.30,95% CI 1.10-1.54) 3
• CCB amlodipine was more effective than ACE inhibitor lisinopril in reducing BP, CVD, and stroke events in Black patients 1

Safety Concerns:

• Black patients have a greater risk of angioedema with ACE inhibitors 1

When ACE Inhibitors ARE Indicated in Black Patients

ACE inhibitors should be used in Black patients with the following compelling indications:

• Chronic kidney disease (CKD) - ACE inhibitors or ARBs are recommended as part of multidrug regimens 1
• Heart failure - ACE inhibitors/ARBs plus beta blockers are indicated 1
• Diabetes with nephropathy - ACE inhibitors/ARBs are specifically recommended 1
• Post-myocardial infarction with coronary disease - Standard indication regardless of race

Combination Therapy: Where ACE Inhibitors Work Well

Most Black patients require ≥2 antihypertensive medications to achieve BP control 1. In combination therapy, ACE inhibitors are effective:

• ACE inhibitor + thiazide diuretic produces similar BP lowering in Black and white patients 1
• ACE inhibitor + CCB produces similar BP lowering across racial groups 1
• The reduced efficacy seen with monotherapy disappears in combination therapy 4
• Single-tablet combinations including a diuretic or CCB may be particularly effective 1

Important Caveat

Racial differences should NOT be the basis for excluding ACE inhibitors from combination therapy 1. Once a thiazide diuretic or CCB is on board, adding an ACE inhibitor is appropriate and effective.

Optimal First-Line Agents

Thiazide-Type Diuretics (Preferred):

• Chlorthalidone 12.5-25 mg/day (preferred over hydrochlorothiazide for outcomes data) 1
• Hydrochlorothiazide 25-50 mg/day if chlorthalidone not available
• Superior for preventing heart failure, stroke, and combined CVD events in Black patients 3

Calcium Channel Blockers (Alternative):

• Amlodipine is as effective as chlorthalidone for most outcomes except heart failure prevention 1
• Good alternative when thiazides are not tolerated

Clinical Algorithm for Black Patients with Uncomplicated Hypertension

1. Stage 1 hypertension (130-139/80-89 mmHg): Start with single agent - thiazide diuretic or CCB
2. Stage 2 hypertension (≥140/90 mmHg or >20/10 mmHg above target): Start with two agents - thiazide diuretic + CCB, or either agent + ACE inhibitor/ARB 1
3. If BP not controlled on 2 drugs: Add third agent from different class, including ACE inhibitor/ARB 1
4. Target BP: <130/80 mmHg 1

Evidence Quality and Nuances

The guideline recommendations are based on high-quality randomized controlled trials, particularly ALLHAT which included over 15,000 Black patients 3. However, recent literature questions whether race should be used as a primary determinant of therapy 5, noting:

• Substantial overlap in individual responses exists between Black and white patients
• Race is a social construct, not a biological determinant
• Other factors (salt sensitivity, renin levels) may be more relevant than race alone

Despite these valid concerns, current evidence-based guidelines maintain race-specific recommendations because the population-level data consistently show differential responses 1. Emerging evidence suggests ACE inhibitors may provide anti-fibrotic benefits in Black patients with left ventricular hypertrophy beyond BP lowering 6, which may influence future recommendations.

Key Pitfalls to Avoid

• Don't avoid ACE inhibitors entirely - they remain important for combination therapy and compelling indications
• Don't use ACE inhibitors as monotherapy in uncomplicated hypertension in Black patients - outcomes data show inferiority
• Don't underdose thiazides - chlorthalidone 12.5-25 mg or HCTZ 25-50 mg are needed for proven outcomes 1
• Don't forget most patients need ≥2 drugs - be prepared to escalate therapy early, especially in Black patients 1